美国 · SEC FORM 4
ENANTA PHARMACEUTICALS INC
ENTA · Nasdaq · CIK 0001177648 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
0 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-02-12 · Luly Jay R..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,552,994
- 上期报告
- 2,600,199
- 日均成交量
- 277,685
- 回补天数
- 9.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-02-12 | Luly Jay R. | 买入 (P) | Common Stock | 45,000 | USD 5.69 | USD 256,050 | SEC 申报 ↗ |
Form 4 申报证据
36 transaction lines in the latest 365-day window; 273 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. | 代扣税 (F) | Common Stock | 1,467 | USD 13.34 | USD 19,570 | SEC 申报 ↗ |
| 2026-02-12 | Rottinghaus Scott T. | 代扣税 (F) | Common Stock | 3,413 | USD 14.25 | USD 48,635 | SEC 申报 ↗ |
| 2026-02-12 | Rottinghaus Scott T. | 奖励／授予 (A) | Common Stock | 6,875 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. | 代扣税 (F) | Common Stock | 1,467 | USD 13.34 | USD 19,570 | SEC 申报 ↗ |
| 2026-02-12 | Rottinghaus Scott T. | 代扣税 (F) | Common Stock | 3,413 | USD 14.25 | USD 48,635 | SEC 申报 ↗ |
| 2026-02-12 | Rottinghaus Scott T. | 奖励／授予 (A) | Common Stock | 6,875 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Or Yat Sun | 代扣税 (F) | Common Stock | 3,413 | USD 14.25 | USD 48,635 | SEC 申报 ↗ |
| 2026-02-12 | Or Yat Sun | 奖励／授予 (A) | Common Stock | 6,875 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Luu Brendan | 代扣税 (F) | Common Stock | 3,257 | USD 14.25 | USD 46,412 | SEC 申报 ↗ |
| 2026-02-12 | Luu Brendan | 奖励／授予 (A) | Common Stock | 6,562 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Luly Jay R. | 代扣税 (F) | Common Stock | 6,155 | USD 14.25 | USD 87,709 | SEC 申报 ↗ |
| 2026-02-12 | Luly Jay R. | 奖励／授予 (A) | Common Stock | 20,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Kowalsky Matthew Paul | 代扣税 (F) | Common Stock | 1,902 | USD 14.25 | USD 27,104 | SEC 申报 ↗ |
| 2026-02-12 | Kowalsky Matthew Paul | 奖励／授予 (A) | Common Stock | 5,493 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Kieffer Tara Lynn | 代扣税 (F) | Common Stock | 3,257 | USD 14.25 | USD 46,412 | SEC 申报 ↗ |
| 2026-02-12 | Kieffer Tara Lynn | 奖励／授予 (A) | Common Stock | 6,562 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-05 | Trout Harry R. III | 卖出 (S) | Common Stock | 542 | USD 14.23 | USD 7,713 | SEC 申报 ↗ |
| 2025-12-05 | Rottinghaus Scott T. | 卖出 (S) | Common Stock | 798 | USD 14.23 | USD 11,356 | SEC 申报 ↗ |
| 2025-12-05 | Or Yat Sun | 卖出 (S) | Common Stock | 2,390 | USD 14.23 | USD 34,010 | SEC 申报 ↗ |
| 2025-12-05 | Luu Brendan | 卖出 (S) | Common Stock | 1,394 | USD 14.23 | USD 19,837 | SEC 申报 ↗ |
| 2025-12-05 | Luly Jay R. | 卖出 (S) | Common Stock | 4,743 | USD 14.23 | USD 67,493 | SEC 申报 ↗ |
| 2025-12-05 | Kieffer Tara Lynn | 卖出 (S) | Common Stock | 2,106 | USD 14.23 | USD 29,968 | SEC 申报 ↗ |
| 2025-12-05 | Capps Kathleen S. | 卖出 (S) | Common Stock | 323 | USD 14.23 | USD 4,596 | SEC 申报 ↗ |
| 2025-12-02 | Trout Harry R. III | 卖出 (S) | Common Stock | 380 | USD 13.96 | USD 5,305 | SEC 申报 ↗ |
| 2025-12-02 | Capps Kathleen S. | 卖出 (S) | Common Stock | 207 | USD 13.96 | USD 2,890 | SEC 申报 ↗ |
| 2025-12-01 | Trout Harry R. III | 代扣税 (F) | Common Stock | 105 | USD 14.12 | USD 1,483 | SEC 申报 ↗ |
| 2025-12-01 | Or Yat Sun | 代扣税 (F) | Common Stock | 753 | USD 14.12 | USD 10,632 | SEC 申报 ↗ |
| 2025-12-01 | Luu Brendan | 代扣税 (F) | Common Stock | 498 | USD 14.12 | USD 7,032 | SEC 申报 ↗ |
| 2025-12-01 | Luly Jay R. | 代扣税 (F) | Common Stock | 1,885 | USD 14.12 | USD 26,616 | SEC 申报 ↗ |
| 2025-12-01 | Kieffer Tara Lynn | 代扣税 (F) | Common Stock | 753 | USD 14.12 | USD 10,632 | SEC 申报 ↗ |
| 2025-12-01 | Capps Kathleen S. | 代扣税 (F) | Common Stock | 85 | USD 14.12 | USD 1,200 | SEC 申报 ↗ |
| 2025-11-25 | Trout Harry R. III | 奖励／授予 (A) | Common Stock | 6,463 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-25 | Capps Kathleen S. | 奖励／授予 (A) | Common Stock | 3,163 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ENTA |
| CIK | 0001177648 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 273 transaction lines from 2020-01-02 to 2026-08-08 1 P purchase lines · 69 S sale lines · 203 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.